Targets › F3
5 programs from 4 companies in 5 trials: 2 Phase 2, 2 Phase 1, 1 Phase 4; Oncology, Neurology; next expected readout Mar 2027.
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. (UniProt, P13726)
Open in Phaseline: the race on F3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Tisotumab Vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 4 | Cervical Cancer | Dec 2028 |
| Pfizer | tisotumab vedotin Tubulin inhibitor; Coagulation factor III binding agent | Tubulin, F3 | Phase 2 | Colorectal Neoplasms | Mar 2027 |
| Zhujiang Hospital | Bevifibatide citrate injection Tissue factor pathway inhibitor (TFPI) analog | F3 | Phase 2 | Ischemic Stroke, Acute | – |
| Adcendo ApS | ADCE-T02 Tissue factor targeted antibody-drug conjugate | F3 | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Sutro Biopharma | STRO-004 Tissue Factor (TF) antagonist; antibody-drug conjugate targeting TF-expressing cancer cell | F3 | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Dec 2027 |
Colorectal Neoplasms (1) Cervical Cancer (1) Head and Neck Squamous Cell Carcinoma HNSCC (1) Ischemic Stroke, Acute (1) Advanced Solid Tumor (1)
mixed (2), small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.